Meda's sales and earnings grow
This article was originally published in Scrip
Executive Summary
The Swedish speciality pharmaceutical group Meda posted 28% sales growth in the third quarter, to SEK3.02 billion ($422 million). Sales of the company's new formulation of azelastine for rhinitis, Astepro, were SEK75 million, while the older formulation, Astelin, saw sales decline from SEK279 million to SEK261 million.